Castle Biosciences (CSTL) PT Lowered to $40 at Canaccord
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts CSTL Hot Sheet
Price: $35.14 --0%
Rating Summary:
11 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 17 | New: 12
Rating Summary:
11 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 17 | New: 12
Join SI Premium – FREE
Canaccord analyst Kyle Mikson lowered the price target on Castle Biosciences (NASDAQ: CSTL) to $40.00 (from $50.00) while maintaining a Buy rating.
You May Also Be Interested In
- JPMorgan Downgrades LG Energy Solution (373220:KS) to Neutral
- Minimax Group Inc (100:HK) PT Lowered to HK$200 at JPMorgan
- Yonyou Network Technology Co Ltd (600588:CH) PT Lowered to RMB5.60 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
